122 related articles for article (PubMed ID: 37078951)
1. Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in Pancreatic Ductal Adenocarcinoma Microenvironment.
Yin Z; Chen S
Pancreas; 2022 Oct; 51(9):1235-1247. PubMed ID: 37078951
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer.
Jing Y; Wang F; Zhang K; Chen Z
BMC Med Genomics; 2022 Apr; 15(1):96. PubMed ID: 35468838
[TBL] [Abstract][Full Text] [Related]
3. Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines.
Sun X; Chen Q; Zhang L; Chen J; Zhang X
Math Biosci Eng; 2021 Jul; 18(5):6262-6287. PubMed ID: 34517533
[TBL] [Abstract][Full Text] [Related]
4. Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment.
Zeng Q; Sun S; Li Y; Li X; Li Z; Liang H
Front Oncol; 2019; 9():1555. PubMed ID: 32117786
[No Abstract] [Full Text] [Related]
5. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.
Yin Z; Ma T; Chen S; Yu M
Cancer Biomark; 2023; 36(3):231-250. PubMed ID: 36938723
[TBL] [Abstract][Full Text] [Related]
6. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL
J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma.
Huang J; Chen Z; Ding C; Lin S; Wan D; Ren K
Front Oncol; 2021; 11():711402. PubMed ID: 34497764
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma.
Robin F; Angenard G; Cano L; Courtin-Tanguy L; Gaignard E; Khene ZE; Bergeat D; Clément B; Boudjema K; Coulouarn C; Sulpice L
Br J Cancer; 2020 Jul; 123(1):72-80. PubMed ID: 32376891
[TBL] [Abstract][Full Text] [Related]
10. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.
Zhou J; Hui X; Mao Y; Fan L
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31311829
[TBL] [Abstract][Full Text] [Related]
12. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma.
Wente MN; Gaida MM; Mayer C; Michalski CW; Haag N; Giese T; Felix K; Bergmann F; Giese NA; Friess H
Int J Oncol; 2008 Aug; 33(2):297-308. PubMed ID: 18636150
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Liu Q; Cui M; Wang M; Hua S; Gao J; Liao Q
Front Immunol; 2021; 12():774435. PubMed ID: 35046938
[TBL] [Abstract][Full Text] [Related]
14. Expression and clinical significance of CXC chemokines in the glioblastoma microenvironment.
Li C; Deng H; Zhou Y; Ye Y; Zhao S; Liang S; Cai S; Lin J; Tang Y; Wu Y
Life Sci; 2020 Nov; 261():118486. PubMed ID: 32976881
[TBL] [Abstract][Full Text] [Related]
15. CXC Chemokines as Therapeutic Targets and Prognostic Biomarkers in Skin Cutaneous Melanoma Microenvironment.
Zhou X; Peng M; He Y; Peng J; Zhang X; Wang C; Xia X; Song W
Front Oncol; 2021; 11():619003. PubMed ID: 33767987
[TBL] [Abstract][Full Text] [Related]
16. Systematic Analysis of CXC Chemokine-Vascular Endothelial Growth Factor A Network in Colonic Adenocarcinoma from the Perspective of Angiogenesis.
Situ Y; Lu X; Cui Y; Xu Q; Deng L; Lin H; Shao Z; Chen J
Biomed Res Int; 2022; 2022():5137301. PubMed ID: 36246978
[TBL] [Abstract][Full Text] [Related]
17. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
18. The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells.
Kung PJ; Lai TY; Cao J; Hsu LC; Chiang TC; Ou-Yang P; Tsai CY; Tsai YF; Lin CW; Chen CC; Tsai MK; Tien YW; Lee CY
Cancer Immunol Immunother; 2022 Mar; 71(3):705-718. PubMed ID: 34374812
[TBL] [Abstract][Full Text] [Related]
19. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
Liu XD; Zhang ZW; Wu HW; Liang ZY
Pathol Res Pract; 2021 Jan; 217():153313. PubMed ID: 33341545
[TBL] [Abstract][Full Text] [Related]
20. Analysis of therapeutic targets and prognostic biomarkers of CXC chemokines in cervical cancer microenvironment.
Kong W; Zhao G; Chen H; Wang W; Shang X; Sun Q; Guo F; Ma X
Cancer Cell Int; 2021 Jul; 21(1):399. PubMed ID: 34321012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
